Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Medicis Pharmaceutical Corporation - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 26 PAGES: 41

Medicis Pharmaceutical Corporation (Medicis) is a specialty pharmaceutical company. It discovers, develops and markets pharmaceutical products for the treatment of dermatological and aesthetic conditions. The company provides a wide range of products addressing various conditions, including acne, fungal infections, facial wrinkles, photoaging, rosacea, psoriasis, hyperpigmentation, seborrheic dermatitis and cosmesis. The products offered by the company include Dysport, Perlane, Restylane, Solodyn, Vanos and Ziana, among others. It operates in the US, Canada and Europe as a subsidiary of Valeant Pharmaceuticals International, Inc.

More Info
									            Medicis Pharmaceutical Corporation - Financial and Strategic SWOT
                                    Analysis Review
        Reference Code: GDPH6317FSA                                                                                           Publication Date: MAR 2013

          7720 North Dobson Road                             Phone              +1 602 8088800                  Revenue          721.1 (million USD)
          Scottsdale, AZ                                     Fax                +1 602 8080822                  Net Profit       126.08 (million USD)
          85256                                              Website            www.Medicis.com                 Employees        646
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange                                           Industry
                                                                                                                                 Healthcare

       Company Overview
       Medicis Pharmaceutical Corporation (Medicis) is a specialty pharmaceutical company. It discovers, develops and markets
       pharmaceutical products for the treatment of dermatological and aesthetic conditions. The company provides a wide range of
       products addressing various conditions, including acne, fungal infections, facial wrinkles, photoaging, rosacea, psoriasis,
       hyperpigmentation, seborrheic dermatitis and cosmesis. The products offered by the company include Dysport, Perlane,
       Restylane, Solodyn, Vanos and Ziana, among others. It operates in the US, Canada and Europe as a subsidiary of Valeant
       Pharmaceuticals International, Inc.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Medicis Pharmaceutical Corporation, SWOT Analysis
         Jonah Shacknai                      Chairman                                 Strengths                              Weaknesses
         Arthur G. Altschul, Jr.             Director
                                                                                      Broad Product Portfolio                Lack of Manufacturing Facilities
         Spencer Davidson                    Director
                                                                                      Orphan Drug Status –                   Legal Proceedings
         Stuart Diamond                      Director
                                                                                      Ammonul
         Peter S. Knight                     Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Sturdy Research and                    Reimbursement Issues
         Medicis Pharmaceutical Corporation                                           Development Effort
                                                                                                                             Tightening of FDA’s Regulatory
        Share Price (USD) as on 10-Dec-                                   0.0         Research Collaborations                Oversight
        2012
        EPS (USD)                                                        1.59
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                          0.0        GlobalData

        Enterprise Value (million USD)                                    NA
        Shares Outstanding (million)                                       58
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Dec 17, 2012         Valeant Pharma         Lays    Off   200     Medicis
                                                                                                           Employees
                                                                                      Nov 08, 2012         Medicis Pharma Reports Revenue Of $180.2m
                                                                                                           In Q3 2012
                                                                                      Aug 08, 2012         Medicis Pharma Reports Revenue Of $196.6m
                                                                                                           In Q2 2012
                                                                                      May 08, 2012         Medicis Reports Revenue Of $201.7m In Q1
                                                                                                           2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Medicis Pharmaceutical Corporation - Financial and Strategic                                                                     Reference Code: GDPH6317FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Medicis Pharmaceutical Corporation - Key Facts ............................................................................................................................... 5
       Medicis Pharmaceutical Corporation - Key Employees ...................................................................................................................... 6
       Medicis Pharmaceutical Corporation - Key Employee Biographies .................................................................................................... 7
       Medicis Pharmaceutical Corporation - Major Products and Services ................................................................................................. 8
       Medicis Pharmaceutical Corporation - Pharmaceutical Pipeline Products Data ................................................................................. 9
          Medicis Pharmaceutical Corporation, Pipeline Products by Therapy Area ..................................................................................... 9
          Medicis Pharmaceutical Corporation, Pipeline Products by Development Phase......................................................................... 10
       Medicis Pharmaceutical Corporation - History.................................................................................................................................. 12
       Medicis Pharmaceutical Corporation - Company Statement ............................................................................................................ 15
       Medicis Pharmaceutical Corporation - Locations And Subsidiaries.................................................................................................. 16
          Head Office ................................................................................................................................................................................... 16
          Other Locations & Subsidiaries ..................................................................................................................................................... 16
       Section 2 – Company Analysis ......................................................................................................................................................... 18
       Medicis Pharmaceutical Corporation - Business Description ........................................................................................................... 18
       Medicis Pharmaceutical Corporation - Corporate Strategy............................................................................................................... 19
       Medicis Pharmaceutical Corporation - SWOT Analysis .................................................................................................................... 20
          SWOT Analysis - Overview........................................................................................................................................................... 20
          Medicis Pharmaceutical Corporation - Strengths .......................................................................................................................... 20
             Strength - Broad Product Portfolio ............................................................................................................................................ 20
             Strength - Orphan Drug Status – Ammonul............................................................................................................................... 20
          Medicis Pharmaceutical Corporation - Weaknesses ..................................................................................................................... 20
             Weakness - Lack of Manufacturing Facilities ............................................................................................................................ 20
             Weakness - Legal Proceedings ................................................................................................................................................. 20
          Medicis Pharmaceutical Corporation - Opportunities .................................................................................................................... 21
             Opportunity - Sturdy Research and Development Effort ........................................................................................................... 21
             Opportunity - Research Collaborations ..................................................................................................................................... 21
             Opportunity - Rising Healthcare Expenditure in the US............................................................................................................. 22
          Medicis Pharmaceutical Corporation - Threats ............................................................................................................................. 22
             Threat - Reimbursement Issues ................................................................................................................................................ 22
             Threat - Tightening of FDA’s Regulatory Oversight ................................................................................................................... 22
             Threat - Intense Competition ..................................................................................................................................................... 22
       Medicis Pharmaceutical Corporation - Key Competitors .................................................................................................................. 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30
          Medicis Pharmaceutical Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013................................... 30


Medicis Pharmaceutical Corporation - Financial and Strategic                                                                                                     Reference Code: GDPH6317FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Medicis Pharmaceutical Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 .................................. 31
       Medicis Pharmaceutical Corporation, Recent Deals Summary ........................................................................................................ 32
       Section 5 – Company’s Recent Developments ........................
								
To top